Subtyping Pancreatic Cancer

Andrew V Biankin; Anirban Maitra

doi:10.1016/j.ccell.2015.09.020

Subtyping Pancreatic Cancer

Cancer Cell. 2015 Oct 12;28(4):411-413. doi: 10.1016/j.ccell.2015.09.020.

Authors

Andrew V Biankin¹, Anirban Maitra²

Affiliations

¹ Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, Scotland G61 1BD, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow G31 2ER, UK; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool, NSW 2170, Australia. Electronic address: andrew.biankin@glasgow.ac.uk.
² Pathology and Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 USA.

PMID: 26461089
DOI: 10.1016/j.ccell.2015.09.020

Abstract

The complex tumor microenvironment can make molecularly subtyping cancer using mRNA expression challenging, particularly for cancers with low epithelial content, such as pancreatic cancer. In a recent edition of Nature Genetics, Moffitt and colleagues show that subtracting normal epithelial transcripts can provide insights into the molecular pathology of pancreatic cancer.

Publication types

Comment

MeSH terms

Adenocarcinoma / pathology*
Animals
Carcinoma, Pancreatic Ductal / pathology*
Female
Humans
Male
Pancreatic Neoplasms / pathology*
Stromal Cells / pathology*

Abstract

Publication types

MeSH terms

Grants and funding